![]() |
PARIS, March 4, 2024 /PRNewswire/ — IFF has launched an advertising campaign featuring staple tools of the art of perfumery. The campaign is appearing today in select publications and online.
“IFF perfumers are artists of the invisible, who craft olfactive works of art, connecting with consumers around the world through the scents they create for niche to global brands,” said Sabrya Meflah, IFF president of fine fragrance. “This campaign celebrates their art, which carries a unique emotional power.”
The advertising campaign was shot by renowned luxury, perfume and haute-jewelry photographer, Helmut Stelzenberger, who has worked on ad campaigns for Chanel, Van Cleef, Cartier and others.
The campaign visuals feature the iconic blue-glass bottle—a staple of the IFF brand—held within hands representing perfumery craftsmanship. Meanwhile, the perfumer’s tools—blotters, beakers, pipettes and vials—stand on the scale perfumers use to compound their fragrance formulas. The scale’s digital display shows a date of significance in IFF’s long history: 1889, the year predecessor company Polak & Schwarz was founded, a testimony of the company’s longstanding legacy.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn.
© 2024 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
Contact:
Judith Gross
VP Scent Communication and Branding
+33630097462
[email protected]
ข่าวที่เกี่ยวข้อง
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
- 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC


